Advertisement
Advertisement
U.S. Markets closed
S&P Futures
3,898.00 -18.25 (-0.47%) Dow Futures
31,347.00 -140.00 (-0.44%) Nasdaq Futures
12,086.00 -54.50 (-0.45%) Russell 2000 Futures
1,752.40 -9.30 (-0.53%) Crude Oil
106.02 -1.60 (-1.49%) Gold
1,830.80 +0.50 (+0.03%)
Puma Biotechnology, Inc. (PBYI)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 2.9000 |
| Open | 2.9500 |
| Bid | 2.8500 x 1800 |
| Ask | 3.0000 x 2900 |
| Day's Range | 2.8100 - 3.1300 |
| 52 Week Range | 1.6000 - 9.7700 |
| Volume | |
| Avg. Volume | 491,198 |
| Market Cap | 116.524M |
| Beta (5Y Monthly) | 1.01 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1980 |
| Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.40 |
- Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES, June 07, 2022--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 3, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 38,125 shares of Puma common stock to six new non-executive employees.
- Business Wire
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting
LOS ANGELES, June 06, 2022--Puma Biotechnology presented results from its SUMMIT Trial, Metastatic Breast Cancer, in a poster presentation at ASCO 2022.
- Business Wire
Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT ‘Basket’ Trial of Neratinib at the ASCO 2022 Annual Meeting
LOS ANGELES, June 04, 2022--Puma Biotechnology presented Biliary Tract Cancer results from its SUMMIT Trial in a poster presentation at ASCO 2022.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
